All patients were positive for actin (positive control) and 13/20 had detectable CTCs as indicated by the presence of at least one additional tumor-associated transcript (i.e., full-length AR, PSA, and/or prostate-specific membrane antigen) using the AdnaTest (Table 2). The gene discussed is FOLH1; the disease is neoplasm.